Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
April 24, 2019
Jeffrey Dao, Operations & Business Development Officer to present HighTide’s HTD1801 for primary sclerosing cholangitis (PSC) at the World Orphan Drug Congress USA 2019 in Oxon Hill, MD...
April 04, 2019
[Rockville, Maryland, Dec. 11, 2018] — HighTide Therapeutics, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9.
December 11, 2018